Celldex Therapeutics (CLDX) News Today $20.66 -0.05 (-0.24%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$20.66 0.00 (-0.02%) As of 05/2/2025 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Celldex Therapeutics, Inc. (NASDAQ:CLDX) Given Consensus Recommendation of "Moderate Buy" by AnalystsCelldex Therapeutics, Inc. (NASDAQ:CLDX - Get Free Report) has been given an average recommendation of "Moderate Buy" by the ten analysts that are presently covering the company, Marketbeat reports. Two analysts have rated the stock with a hold rating, seven have given a buy rating and one has givMay 4 at 2:43 AM | marketbeat.comCelldex Therapeutics (CLDX) Projected to Post Earnings on MondayMay 4 at 1:53 AM | americanbankingnews.comNovo Holdings A S Buys 36,337 Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX)Novo Holdings A S boosted its stake in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 3.8% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,000,000 shares of the biopharmaceutical company's stock afteMay 3 at 8:09 AM | marketbeat.comNebula Research & Development LLC Acquires Shares of 14,027 Celldex Therapeutics, Inc. (NASDAQ:CLDX)Nebula Research & Development LLC bought a new position in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund bought 14,027 shares of the biopharmaceutMay 3 at 4:58 AM | marketbeat.comCelldex Therapeutics, Inc. (NASDAQ:CLDX) Given Consensus Recommendation of "Moderate Buy" by BrokeragesMay 2 at 2:45 AM | americanbankingnews.comCelldex Therapeutics (NASDAQ:CLDX) Shares Gap Up - What's Next?Celldex Therapeutics (NASDAQ:CLDX) Shares Gap Up - Still a Buy?April 30, 2025 | marketbeat.comCelldex Therapeutics (NASDAQ:CLDX) Now Covered by Canaccord Genuity GroupCanaccord Genuity Group initiated coverage on shares of Celldex Therapeutics in a research report on Monday. They set a "buy" rating and a $64.00 price objective for the company.April 30, 2025 | marketbeat.comCelldex Therapeutics, Inc. (NASDAQ:CLDX) Shares Bought by Price T Rowe Associates Inc. MDPrice T Rowe Associates Inc. MD increased its position in Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 23.5% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 3,557,136 shares of the biopharmaApril 30, 2025 | marketbeat.comCelldex Therapeutics (CLDX) Expected to Announce Earnings on MondayCelldex Therapeutics (NASDAQ:CLDX) will be releasing its Q1 2025 earnings before the market opens on Monday, May 5. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-5-celldex-therapeutics-inc-stock/)April 30, 2025 | marketbeat.comBarclays PLC Increases Holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX)Barclays PLC grew its holdings in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 9.6% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 142,914 shares of the biopharmaceutical company's stock after buyinApril 30, 2025 | marketbeat.comCanaccord Genuity Group Initiates Coverage on Celldex Therapeutics (NASDAQ:CLDX)April 30, 2025 | americanbankingnews.comT. Rowe Price Investment Management Inc. Decreases Stock Holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX)T. Rowe Price Investment Management Inc. cut its holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 2.1% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,697,498 shares of the biopharApril 29, 2025 | marketbeat.com3CLDX : Analyst Expectations For Celldex Therapeutics's FutureApril 29, 2025 | benzinga.comGuggenheim Capital LLC Buys Shares of 23,797 Celldex Therapeutics, Inc. (NASDAQ:CLDX)Guggenheim Capital LLC purchased a new position in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 23,797 shares of the biopharmaceutical coApril 28, 2025 | marketbeat.comCelldex Therapeutics, Inc. (NASDAQ:CLDX) Shares Sold by XTX Topco LtdXTX Topco Ltd reduced its holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 75.5% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 11,256 shares of the biopharmaceutical company's stock after selling 34,661 sApril 28, 2025 | marketbeat.com15,800 Shares in Celldex Therapeutics, Inc. (NASDAQ:CLDX) Purchased by NatixisNatixis purchased a new stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 15,800 shares of the biopharmaceutical company's stock, valued at approximatelApril 27, 2025 | marketbeat.comCelldex Therapeutics, Inc. (NASDAQ:CLDX) Shares Sold by Canada Pension Plan Investment BoardCanada Pension Plan Investment Board trimmed its holdings in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 42.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 37,000 shares of the biopharmApril 27, 2025 | marketbeat.comJump Financial LLC Acquires Shares of 16,513 Celldex Therapeutics, Inc. (NASDAQ:CLDX)Jump Financial LLC bought a new stake in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 16,513 shares of the biopharmaceutical company's stock, valued at approxApril 27, 2025 | marketbeat.comJPMorgan Chase & Co. Raises Position in Celldex Therapeutics, Inc. (NASDAQ:CLDX)JPMorgan Chase & Co. lifted its stake in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 103.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 85,545 shares of the biopharmaceutical company's stock aApril 26, 2025 | marketbeat.comRenaissance Technologies LLC Makes New $3.45 Million Investment in Celldex Therapeutics, Inc. (NASDAQ:CLDX)Renaissance Technologies LLC bought a new stake in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 136,588 shares of the biopharmaceuticApril 25, 2025 | marketbeat.comSilverarc Capital Management LLC Acquires 119,560 Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX)Silverarc Capital Management LLC grew its stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 82.5% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 264,560 shares of the biopharmaceutical company's stock afterApril 24, 2025 | marketbeat.comEversept Partners LP Increases Position in Celldex Therapeutics, Inc. (NASDAQ:CLDX)Eversept Partners LP grew its holdings in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 27.4% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 719,836 shares of the biopharmaceutical company's stock after purchasing an additional 154,934April 24, 2025 | marketbeat.comCelldex Therapeutics (NASDAQ:CLDX) Trading 4.8% Higher - Time to Buy?Celldex Therapeutics (NASDAQ:CLDX) Trading Up 4.8% - Time to Buy?April 23, 2025 | marketbeat.comCommit To Purchase Celldex Therapeutics At $15, Earn 20.1% Annualized Using OptionsApril 23, 2025 | nasdaq.comCelldex Therapeutics, Inc. (NASDAQ:CLDX) Shares Acquired by Rock Springs Capital Management LPRock Springs Capital Management LP increased its stake in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 10.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,222,182 shares of tApril 23, 2025 | marketbeat.comAffinity Asset Advisors LLC Sells 115,008 Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX)Affinity Asset Advisors LLC reduced its position in Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 92.0% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 9,992 shares of the biopharmaceutical company's stock after sellingApril 17, 2025 | marketbeat.comCelldex Therapeutics, Inc. (NASDAQ:CLDX) Shares Sold by Fmr LLCFmr LLC lowered its stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 19.4% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 4,857,668 shares of the biopharmaceutical company's stock afterApril 16, 2025 | marketbeat.com17,244 Shares in Celldex Therapeutics, Inc. (NASDAQ:CLDX) Bought by ExodusPoint Capital Management LPExodusPoint Capital Management LP bought a new stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 17,244 shares of tApril 15, 2025 | marketbeat.comCelldex Therapeutics (NASDAQ:CLDX) Reaches New 1-Year Low - Should You Sell?Celldex Therapeutics (NASDAQ:CLDX) Sets New 12-Month Low - Here's WhyApril 9, 2025 | marketbeat.comCelldex Therapeutics, Inc. (NASDAQ:CLDX) Receives Average Rating of "Moderate Buy" from AnalystsCelldex Therapeutics, Inc. (NASDAQ:CLDX - Get Free Report) has received an average recommendation of "Moderate Buy" from the nine brokerages that are currently covering the company, MarketBeat reports. Two analysts have rated the stock with a hold rating, six have given a buy rating and one has asApril 8, 2025 | marketbeat.comCinctive Capital Management LP Increases Stock Position in Celldex Therapeutics, Inc. (NASDAQ:CLDX)Cinctive Capital Management LP grew its holdings in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 140.6% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 81,320 shares of the biopharmaceutical company'sApril 5, 2025 | marketbeat.com23,790 Shares in Celldex Therapeutics, Inc. (NASDAQ:CLDX) Bought by Bryce Point Capital LLCBryce Point Capital LLC acquired a new position in Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 23,790 shares of the biopharmaceutiApril 5, 2025 | marketbeat.comWellington Management Group LLP Sells 267,766 Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX)Wellington Management Group LLP decreased its position in Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 2.9% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 8,975,833 shares of the biopharmaceutical company's stock after selling 26April 4, 2025 | marketbeat.comCelldex Therapeutics (NASDAQ:CLDX) Shares Down 6.5% - Here's What HappenedCelldex Therapeutics (NASDAQ:CLDX) Stock Price Down 6.5% - Here's WhyApril 3, 2025 | marketbeat.comPictet Asset Management Holding SA Sells 48,273 Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX)Pictet Asset Management Holding SA lowered its stake in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 4.2% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,090,173 shares of the biopharmaceutical cApril 2, 2025 | marketbeat.comAmerican Century Companies Inc. Has $15.38 Million Stock Holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX)American Century Companies Inc. increased its holdings in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 46.5% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 608,457 shares of the biopharmaceutical cApril 2, 2025 | marketbeat.comCelldex Therapeutics (NASDAQ:CLDX) Hits New 12-Month Low - Time to Sell?Celldex Therapeutics (NASDAQ:CLDX) Reaches New 1-Year Low - Here's What HappenedApril 1, 2025 | marketbeat.comCelldex Therapeutics (NASDAQ:CLDX) Trading Down 3.7% - Here's WhyCelldex Therapeutics (NASDAQ:CLDX) Trading Down 3.7% - Here's What HappenedMarch 26, 2025 | marketbeat.comCelldex Therapeutics, Inc. (NASDAQ:CLDX) Shares Purchased by Fox Run Management L.L.C.Fox Run Management L.L.C. boosted its stake in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 149.8% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 23,290 shares of the biopharmaceutical company's stock after buying an additMarch 25, 2025 | marketbeat.comCelldex initiated with an Overweight at Morgan StanleyMarch 21, 2025 | markets.businessinsider.comCelldex Therapeutics (NASDAQ:CLDX) Now Covered by Morgan StanleyMorgan Stanley started coverage on shares of Celldex Therapeutics in a research report on Thursday. They issued an "overweight" rating and a $46.00 price objective for the company.March 21, 2025 | marketbeat.comMorgan Stanley Initiates Coverage of Celldex Therapeutics (CLDX) with Overweight RecommendationMarch 21, 2025 | msn.com3CLDX : 7 Analysts Have This To Say About Celldex TherapeuticsMarch 21, 2025 | benzinga.comCelldex Therapeutics, Inc. (NASDAQ:CLDX) Given Consensus Rating of "Moderate Buy" by BrokeragesCelldex Therapeutics, Inc. (NASDAQ:CLDX - Get Free Report) has earned an average rating of "Moderate Buy" from the eight ratings firms that are currently covering the company, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold rating, five have given a buy rMarch 13, 2025 | marketbeat.comCantor Fitzgerald Issues Negative Estimate for CLDX EarningsCelldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) - Stock analysts at Cantor Fitzgerald reduced their FY2025 earnings per share (EPS) estimates for shares of Celldex Therapeutics in a report issued on Tuesday, March 4th. Cantor Fitzgerald analyst K. Kluska now forecasts that the biopharmaceuMarch 7, 2025 | marketbeat.comCelldex presents preclinical data from CDX-622 at AAAAI 2025March 4, 2025 | markets.businessinsider.comCelldex Therapeutics to Present at Upcoming Investor ConferencesMarch 4, 2025 | globenewswire.comCelldex Therapeutics, Inc. (NASDAQ:CLDX) Shares Bought by Fisher Asset Management LLCFisher Asset Management LLC raised its position in Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 20.9% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 452,497 shares of the biopharmaceutical company's stock after buying an additional 78,145 shareMarch 4, 2025 | marketbeat.comCelldex Therapeutics (NASDAQ:CLDX) Reaches New 52-Week Low Following Analyst DowngradeCelldex Therapeutics (NASDAQ:CLDX) Reaches New 1-Year Low After Analyst DowngradeMarch 3, 2025 | marketbeat.comCelldex Therapeutics Inc (CLDX) Announces Promising Preclinical Data for CDX-622March 3, 2025 | gurufocus.com Get Celldex Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CLDX and its competitors with MarketBeat's FREE daily newsletter. Email Address CLDX Media Mentions By Week CLDX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CLDX News Sentiment▼1.120.73▲Average Medical News Sentiment CLDX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CLDX Articles This Week▼164▲CLDX Articles Average Week Get Celldex Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CLDX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Ionis Pharmaceuticals News Alkermes News Amicus Therapeutics News Ligand Pharmaceuticals News BioCryst Pharmaceuticals News MannKind News Dynavax Technologies News Innoviva News Novavax News OPKO Health News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CLDX) was last updated on 5/4/2025 by MarketBeat.com Staff From Our PartnersWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTrump to solve American wealth loss?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredWill May start the next "Great Depression?"You probably haven't heard about this yet... But this could be the biggest wealth building opportunity of t...Behind the Markets | Sponsored🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAIEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Celldex Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Celldex Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CLDX Stock Free CLDX Stock Alerts